Pneumococcal immunization in immunocompromised hosts: where do we stand?

References

• Winston DJ, Schiffman G, Wang DC et al. Pneumococcal infections after human bone marrow transplant recipients. Ann. Intern. Med. 91, 835–841 (1979).
   PubMed Web of Science ®Google Scholar
• Engelhard D, Cordonnier C, Shaw P et al. Early and late invasive pneumococcal infection following bone marrow and stem cell transplantation. Br. J. Haematol. 117, 444–450 (2002).
   PubMed Web of Science ®Google Scholar
• Youssef S, Rodriguez G, Rolston KV, Champlin RE, Raad II, Safdar A. Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: Clinical characteristics of infections and vaccine-breakthrough infections, 1989–2005. Medicine 86(2), 69–77 (2007).
   PubMed Web of Science ®Google Scholar
• Wong A, Marrie TJ, Garg S, Kellner JD, Tyrrel GJ; SPAT Group. Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies. Epidemiol. Infect. 138(12), 1804–1810 (2010).
   PubMed Web of Science ®Google Scholar
• Kyaw MH, Rose CE Jr, Fry AM et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J. Infect. Dis. 192(3), 377–386 (2005).
   PubMed Web of Science ®Google Scholar
• Ardanuy C, Marimon JM, Catalayud L et al. Epidemiology of invasive pneumococcal disease in older people in Spain (2007–2009): implications for future vaccinations strategies. Plos ONE 7(8), e43619 (2012).
   Web of Science ®Google Scholar
• Burgos J, Penaranda M, Payeras A et al. Invasive pneumococcal disease in HIV-infected adults: Clinical changes after the introduction of the pneumococcal conjugate vaccine in children. J. Acquir. Immune Defic. Syndr. 59(1), 31–38 (2012).
   PubMed Web of Science ®Google Scholar
• Hammarstrom V, Pauksen K, Azinge J, Oberg GLP. Pneumococcal immunity and response to immunization with pneumococcal vaccine in bone marrow transplant patients: the influence of graft versus host reaction. Support. Care Cancer 1, 195–199 (1993).
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Shcubert R, Behl M et al. Impaired pneumococcal immunity in children after treatment for acute lymphoblastic leukaemia. Br. J. Haematol. 147, 700–705 (2009).
   PubMed Web of Science ®Google Scholar
• Patel SR, Bate J, Borrow R, Heath PT. Serotype-specific pneumococcal antibody concentrations in children treated for acute leukaemia. Arch. Dis. Child. 97, 46–48 (2010).
   PubMed Web of Science ®Google Scholar
• Sarmiento E, Rodriguez-Hernandez C, Rodriguez-Molina J et al. Impaired anti-pneumococcal polysaccharide antibody production and invasive pneumococcal infection following heart transplantation. Int. Immunopharm. 6, 2027–2030 (2006).
   PubMedGoogle Scholar
• Notter DT, Grossman PL, Roseberg SA, Remington JS. Infections in patients with Hodgkin’s disease: a clinical study of 300 consecutive adult patients. Rev. Infect. Dis. 2, 761–800 (1980).
   PubMedGoogle Scholar
• Debbache K, Varon E, Hicheri Y et al. The epidemiology of S pneumoniae infections in hematology and stem cell transplant patients: Are these strains covered by the available anti-pneumococcal vaccines in France? Clin. Microbiol. Infect. 15 865–868 (2009).
   Google Scholar
• Kumar D, Humar A, Plevneshi A et al. Invasive pneumococcal disease in solid organ transplant recipients. Ten-year prospective population surveillance. Am. J. Transplant. 7, 1209–1214 (2007).
   PubMed Web of Science ®Google Scholar
• Kumar D, Humar A, Plevneshi A et al. Invasive pneumococcal disease in adult hematopoietic stem cell transplant recipients: a decade of prospective population-based surveillance. Bone Marrow Transplant. 41, 743–747 (2008).
   PubMed Web of Science ®Google Scholar
• de Bruyn G, Whelan TP, Mulligan MS, Raghu G, Limaye AP. Invasive pneumococcal infections in adult lung transplant recipients. Am. J. Transplant. 4, 1366–1371 (2004).
   PubMedGoogle Scholar
• MMWR. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the advisory committee on immunization practices (ACIP). MMWR 61(40), 816–819 (2012).
   PubMedGoogle Scholar
• Kumashi P, Girgawy E, Tarrand JJ, Rolston KV, Raad II, Safdar A. Streptococcus pneumoniae bacteremia in patients with cancer: Disease characteristics and outcomes in the era of escalating drug resistance (1998–2002). Medicine 84(5), 303–312 (2005).
   PubMed Web of Science ®Google Scholar
• O’Brien K, Ochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect. Dis. 7, 597–606 (2007).
   PubMed Web of Science ®Google Scholar
• Poolman J, Borrow R. Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev. Vaccines 10(3), 307–322 (2011).
   PubMed Web of Science ®Google Scholar
• Blum MD, Dagan R, Mendelman PM et al. A comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers. Vaccine 18(22), 2359–6723 (2000).
   PubMed Web of Science ®Google Scholar
• de Roux A, Schmöle-Thomas B, Siber GR et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin. Infect. Dis. 46(7), 1015–1023 (2008).
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Labopin M, Chesnel V et al. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin. Infect. Dis. 48, 1392–1401 (2009).
   PubMed Web of Science ®Google Scholar
• Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N. Engl. J. Med. 349(14), 1341–1348 (2003).
   PubMed Web of Science ®Google Scholar
• Meeting of the immunization Strategic Advisory Group of Experts, November 2006, conclusions and recommendations. Wkly Epidemiol. Rec. 82(1–2), 1–16 (2007).
   PubMedGoogle Scholar
• Kumar D, Hong Chen M, Wong G et al. A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients. Clin. Infect. Dis. 47, 885–892 (2008).
   Google Scholar
• Cordonnier C, Labopin M, Jansen K et al. Relationship between IgG titers and opsonocytophagocytic activity of antipneumococcal antibodies after immunization with the 7-valent conjugate vaccine in allogeneic stem cell transplant. Bone Marrow Transplant. 9, 1423–1426 (2009).
   Google Scholar
• Kumar D, Rotstein C, Miyata G, Arlen D, Humar A. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J. Infect. Dis. 187, 1639–1645 (2003).
   Google Scholar
• French N, Gordon SB, Mwalukomo T et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N. Engl. J. Med. 362(9), 812–822 (2010).
   PubMed Web of Science ®Google Scholar
• Teshale EH, Hanson D, Flannery B et al. Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-infected adults in the United States, 1998--2003. Vaccine 26(46), 5830–5834 (2008).
   PubMed Web of Science ®Google Scholar
• Kulkarni S, Powles R, Treleaven J et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood 95(12), 3683–3686 (2000).
   PubMed Web of Science ®Google Scholar
• Welniak L, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu. Rev. Immunol. 25, 139–170 (2007).
   PubMed Web of Science ®Google Scholar
• Witherspoon R, Storb R, Ochs HD et al. Recovery of antibody production in human allogeneic marrow graft recipients: influence of time post-transplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment. Blood 58, 360–368 (1981).
   PubMed Web of Science ®Google Scholar
• Madhi SA, Klugman KP, Kuwanda L, Cutland C, Kayhty H, Adrian P. Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination. J. Infect. Dis. 199(8), 1168–1176 (2009).
   PubMed Web of Science ®Google Scholar
• Sogaard OS, Lohse N, Harboe ZB et al. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Clin. Infect. Dis. 51(1), 42–50 (2010).
   PubMed Web of Science ®Google Scholar
• Meisel R, Dilloo D. Pneumococcal vaccination of children after hematopoietic stem cell transplantation: Timing is crucial Clin. Infect. Dis. 45, 397–398 (2007).
   PubMed Web of Science ®Google Scholar
• Patel SR, Ortin M, Cohen BJ et al. Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae Type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation. Clin. Infect. Dis. 44, 625–634 (2007).
   PubMed Web of Science ®Google Scholar
• Meerveld-Eggink A, van der Velden A, Ossenkoppele G, van de Loodsdreacht A, Biesma D, Rijkerts G. Antibody response to polysaccharide conjugate vaccines after nonmyeloablative allogeneic stem cell transplantation. Biol. Bone Marrow Transplant. 15, 1523–1530 (2009).
   PubMed Web of Science ®Google Scholar
• Furth SL, Neu AM, Case B, Lederman HM, Steinhoff M, Fivush B. Pneumococcal polysaccharide vaccine in children with chronic renal disease: A prospective study of antibody response and duration. J. Pediatr. 128, 99–101 (1996).
   PubMed Web of Science ®Google Scholar
• Poolman JT, Frasch CE, Kaÿhty H et al. Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines. Clin. Vaccine Immunol. 17(1), 134–142 (2010).
   PubMed Web of Science ®Google Scholar
• Kumar D, Welsh B, Siegal D, Hong CHen M, Humar A. Immunogenicity of pneumococcal vaccine in renal transplant recipients - Three year follow-up of a randomized trial. Am. J. Transplant. 7, 633–638 (2007).
   PubMed Web of Science ®Google Scholar
• Chilcote RR, Bachner RL, Hammond D. Septicemia and meningitis in children splenectomized for Hodgkin’s disease. N. Engl. J. Med. 295, 798–800 (1976).
   PubMed Web of Science ®Google Scholar
• Foss Abrahamsen A, Høiby EA, Hannisdal E et al. Systemic pneumococcal disease after staging splenectomy for Hodgkin’s disease 1969–1980 without pneumococcal vaccine protection: a follow-up study 1994. Eur. J. Haematol. 58(2), 73–77 (1994).
   Google Scholar
• Meisel R, Toschke AM, Heiliensetzer C, Dilloo D, Laws HJ, von Kries R. Increased risk for invasive pneumococcal diseases in children with acute lymphoblastic leukemia. Br. J. Haematol. 137, 457–460 (2007).
   PubMed Web of Science ®Google Scholar
• Molica S. Infections in chronic lymphocytic leukemia: risk factors, and impact on survival and treatment. Leuk. Lymphoma 13, 203–214 (1994).
   PubMed Web of Science ®Google Scholar
• Nordoy T, Aaberge IS, Husebekk A et al. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Med. Oncol. 19(2), 71–78 (2002).
   Google Scholar
• Sinisalo M, Aittoniemi J, Oivanen P, Kayhty H, Olander RM, Vilpo J. Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia. Br. J. Haematol. 114, 107–110 (2001).
   PubMed Web of Science ®Google Scholar
• Petrasch S, Kühnemund O, Reinacher A et al. Antibody responses of splenectomized patients with non-Hodgkin’s lymphoma to immunization with polyvalent penumococcal vaccines. Clin. Diagn. Lab. Immunol. 4(6), 635–638 (1997).
   PubMedGoogle Scholar
• Hartkamp A, Mulder AH, Rijkers GT, van Velzen-Blad H, Biesma DH. Antibody response to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia. Vaccine 19(13–14), 1671–1677 (2001).
   PubMed Web of Science ®Google Scholar
• Robertson JD, Nagesh K, Jowitt SN et al. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br. J. Cancer. 82(7), 1261–1265 (2000).
   PubMed Web of Science ®Google Scholar
• Safdar A, Rodruiguez GH, Rueda AM et al. Multiple-dose Granulocyte-Macrophage-Colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia. Cancer 113, 383–387 (2008).
   PubMed Web of Science ®Google Scholar
• van der Velden AMT, van Velzen-Blad H, Claessen AME et al. The effect of ranitidine on antibody responses to polysaccharide vaccines in patients with B-cell chronic lymphocytic leukaemia. Eur. J. Haematol. 79, 47–52 (2007).
   PubMed Web of Science ®Google Scholar
• Sklenar I, Schiffman G, Jønsson V et al. Effect of various doses of intravenous polyclonal IgG on in vivo levels of 12 pneumococcal antibodies in patients with chronic lymphocytic leukaemia and multiple myeloma. Oncology 50(6), 466–477 (1993).
   PubMed Web of Science ®Google Scholar
• Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 343(8905), 1059–1063 (1994).
   PubMed Web of Science ®Google Scholar
• Hinge M, Ingels HA, Slotved HC, Mølle I. Serologic response to a 23-valent pneumococcal vaccine administered prior to autologous stem cell transplantation in patients with multiple myeloma. APMIS 120(11), 935–940 (2012).
   PubMed Web of Science ®Google Scholar
• Cherif H, Landgren O, Konradsen HB, Kalin M, Björkholm M. Poor antibody response to pneumococcal polysaccharide vaccination suggests increased susceptibility to pneumococcal infection in splenectomized patients with hematological diseases. Vaccine 24(1), 75–81 (2006).
   PubMed Web of Science ®Google Scholar
• Chan CY, Molrione DC, George S et al. Pneumococcal conjugate vaccine primes for antibody response to polysaccharide pneumococcal vaccine after treatment of Hodgkin’s disease. J. Infect. Dis. 173, 256–258 (1996).
   PubMed Web of Science ®Google Scholar
• Cheng FW, Ip M, Chu YY et al. Humoral response to conjugate pneumococcal vaccine in paediatric oncology patients. Arch. Dis. Child. 97(4), 358–360 (2012).
   PubMed Web of Science ®Google Scholar
• Giebink G, Warkentin P, Ralsay N et al. Titers of antibody to pneumococci in allogeneic bone marrow transplant recipients. J. Infect. Dis. 154, 590–596 (1986).
   PubMed Web of Science ®Google Scholar
• Guinan E, Molrine D, Antin J et al. Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplantation 57(5), 677–684 (1994).
   PubMed Web of Science ®Google Scholar
• Storek J, Dawson M, Lim L et al. Efficacy of donor vaccination before hematopoietic cell transplantation and recipient vaccination both before and early after transplantation. Bone Marrow Transplant. 33(3), 337–346 (2004).
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Labopin M, Chesnel V et al. Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial. Vaccine 28(15), 2730–2734 (2010).
   PubMed Web of Science ®Google Scholar
• Kumar D, Chen MH, Welsh B et al. A randomized, double-blind, trial of antipneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients. Clin. Infect. Dis. 45, 1576–1582 (2007).
   PubMed Web of Science ®Google Scholar
• Molrine DC, Antin JH, Guinan EC et al. Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoeitic cell transplantation. Blood 101, 831–836 (2003).
   PubMed Web of Science ®Google Scholar
• Meisel R, Kuypers L, Dirksen U et al. Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation. Blood 109(6), 2322–2326 (2007).
   PubMed Web of Science ®Google Scholar
• Ljungman P, Cordonnier C, Einsele H et al.; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program; European Blood and Marrow Transplant Group et al. Vaccination of hematopoietic cell transplantation. Bone Marrow Transplant. 44, 521–526 (2009).
   PubMed Web of Science ®Google Scholar
• Antin JH, Guinan E, Avigan D et al. Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. Biol. Bone Marrow Transplant. 11, 213–222 (2005).
   PubMed Web of Science ®Google Scholar
• Linnemann CC, First MR. Risk of pneumococcal infections in renal transplant patients. JAMA 241, 2619–2621 (1979).
   PubMed Web of Science ®Google Scholar
• Amber IJ, Gilbert EM, Schiffman G, Jacobson JA. Increased risk of pneumococcal infections in cardiac transplant recipients. Transplantation 49(1), 122–125 (1990).
   PubMed Web of Science ®Google Scholar
• Dengler TJ, Stmad N, Bühring I et al. Differential immune response to influenza and pneumococcal vaccination in immunosuppressed patients after heart transplantation. Transplantation 66(10), 1340–1347 (1998).
   PubMed Web of Science ®Google Scholar
• Blumberg EA, Brozena SC, Stutman P, Wood D, Phan HM, Musher DM. Immunogenicity of pneumococcal vaccine in heart transplant recipients. Clin. Infect. Dis. 32, 307–310 (2001).
   PubMed Web of Science ®Google Scholar
• Gennery AR, Spickett GP, Wlashaw D et al. Effect of immunosuppression after cardiac transplantation in early chilhood on antibody response to polysaccharide antigen. Lancet 351, 1778–1781 (1998).
   PubMed Web of Science ®Google Scholar
• Gasink LB, Wurcell AG, Kotloff RM, Lautenbach E, Blumberg EA. Low prevalence of prior Streptococcus pneumoniae vaccination among potential lung transplant candidates. Chest 130, 218–221 (2006).
   PubMed Web of Science ®Google Scholar
• Dengler TJ, Strnad N, Zimmermann R et al. Pneumokokkenimpfung nach Herz- und Lebertransplantation. Dtsch. Med. Wschr. 121, 1519–1525 (1996).
   PubMedGoogle Scholar
• McCashland TM, Preheim LC, Gentry-Nielsen MJ. Pneumococcal vaccine response in cirrhosis and liver transplantation. J. Infect. Dis. 181, 757–760 (2000).
   PubMed Web of Science ®Google Scholar
• Danzinger-Isakov L, Kumar D; AST Infectious Diseases Community of Practice. Guidelines for vaccination of solid organ transplant candidates and recipients. Am. J. Transplant. 9( Suppl. 4), S258–S262 (2009).
   Web of Science ®Google Scholar
• Barton M, Wasfy S, Dipchand AI et al. Seven-valent pneumococcal conjugate vaccine in pediatric solid organ transplant recipients: a prospective study of safety and immunogenicity. Pediatr. Infect. Dis. J. 28(8), 688–692 (2009).
   PubMed Web of Science ®Google Scholar
• Lin PL, Michaels MG, Green M et al. Safety and immunogenicity of the American Academy of Pediatrics-Recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients. Pediatrics 116, 160–167 (2005).
   PubMed Web of Science ®Google Scholar
• Gattringer R, WInkler H, Roedler S, Jaksch P, Herkner H, Burgmann H. Immunogenicity of a combined schedule of 7-valent pneumococcal conjugate vaccine followed by a 23-valent polysaccharide vaccine in adult recipients of hear or lung transplants. Transplant. Infect. Dis. 13(5), 540–544 (2011).
   PubMed Web of Science ®Google Scholar
• Feikin DR, Elie CM, Goetz MB et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine 20(3–4), 545–553 (2001).
   PubMed Web of Science ®Google Scholar
• Katerinis I, Hadaya K, Duquesnoy R et al. De novo anti-HLA antibody afer pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am. J. Transplant. 11, 1727–1733 (2011).
   PubMed Web of Science ®Google Scholar
• Madhi SA, Madhi A, Petersen K, Khoosal M, Klugman KP. Impact of human immunodeficiency virus type 1 infection on the epidemiology and outcome of bacterial meningitis in South African children. Int. J. Infect. Dis. 5(3), 119–125 (2001).
   PubMedGoogle Scholar
• Nunes MC, von Gottberg A, de Gouveia L et al. Persistent high burden of invasive pneumococcal disease in South African HIV - infected adults in the era of an antiretroviral treatment program. PLoS ONE 6(11), e27929 (2011).
   PubMed Web of Science ®Google Scholar
• Heffernan RT, Barrett NL, Gallagher KM et al. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995–2000. J. Infect. Dis. 191(12), 2038–2045 (2005).
   PubMed Web of Science ®Google Scholar
• Schuchat A, Broome CV, Hightower A, Costa SJ, Parkin W. Use of surveillance for invasive pneumococcal disease to estimate the size of the immunosuppressed HIV-infected population. JAMA 265(24), 3275–3279 (1991).
   PubMed Web of Science ®Google Scholar
• Gilks CF, Ojoo SA, Ojoo JC et al. Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya. Lancet 347(9003), 718–723 (1996).
   PubMed Web of Science ®Google Scholar
• McEllistrem MC, Mendelsohn AB, Pass MA et al. Recurrent invasive pneumococcal disease in individuals with human immunodeficiency virus infection. J. Infect. Dis. 185(9), 1364–1368 (2002).
   PubMed Web of Science ®Google Scholar
• Nunes MC, von Gottberg A, de Gouveia L et al. The impact of antiretroviral treatment on the burden of invasive pneumococcal disease in South African children: a time series analysis. AIDS 25(4), 453–462 (2011).
   PubMed Web of Science ®Google Scholar
• Cohen AL, Harrison LH, Farley MM et al. Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization. AIDS 24(14), 2253–2262 (2010).
   PubMed Web of Science ®Google Scholar
• Eley B. Immunization in patients with HIV infection: are practical recommendations possible? Drugs 68(11), 1473–1481 (2008).
   PubMed Web of Science ®Google Scholar
• King JC, Jr., Vink PE, Chang I et al. Antibody titers eight months after three doses of a five-valent pneumococcal conjugate vaccine in HIV and non-HIV-infected children less than two years of age. Vaccine 16(4), 361–365 (1998).
   PubMed Web of Science ®Google Scholar
• King JC Jr, Vink PE, Farley JJ et al. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 15(3), 192–196 (1996).
   PubMed Web of Science ®Google Scholar
• King JC Jr, Vink PE, Farley JJ, Smilie M, Parks M, Lichenstein R. Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection. Pediatrics 99(4), 575–580 (1997).
   PubMed Web of Science ®Google Scholar
• Madhi SA, Adrian P, Cotton MF et al. Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. J. Infect. Dis. 202(3), 355–361 (2010).
   PubMed Web of Science ®Google Scholar
• Madhi SA, Adrian P, Kuwanda L, Cutland C, Albrich WC, Klugman KP. Long-term effect of pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae--and associated interactions with Staphylococcus aureus and Haemophilus influenzae colonization--in HIV-Infected and HIV-uninfected children. J. Infect. Dis. 196(11), 1662–1666 (2007).
   PubMed Web of Science ®Google Scholar
• Madhi SA, Kuwanda L, Cutland C, Holm A, Kayhty H, Klugman KP. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr. Infect. Dis. J. 24(5), 410–416 (2005).
   PubMed Web of Science ®Google Scholar
• Spoulou VI, Tsoumas DL, Papaevangelou VG, Mostrou GI, Theodoridou MC. Immunogenicity and immunological memory induced by a 7-valent pneumococcal CRM197 conjugate vaccine in symptomatic HIV-1 infected children. Vaccine 23(46–47), 5289–5293 (2005).
   PubMed Web of Science ®Google Scholar
• Thanee C, Pancharoen C, Likitnukul S et al. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children. Vaccine 29(35), 5886–5891 (2011).
   PubMed Web of Science ®Google Scholar
• Nachman S, Kim S, King J et al. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. Pediatrics 112(1 Pt 1), 66–73 (2003).
   PubMed Web of Science ®Google Scholar
• Abzug MJ, Pelton SI, Song LY et al. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr. Infect. Dis. J. 25(10), 920–929 (2006).
   PubMed Web of Science ®Google Scholar
• Bliss SJ, O’Brien KL, Janoff EN et al. The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease. Lancet Infect. Dis. 8(1), 67–80 (2008).
   PubMed Web of Science ®Google Scholar
• Jones N, Huebner R, Khoosal M, Crewe-Brown H, Klugman K. The impact of HIV on Streptococcus pneumoniae bacteraemia in a South African population. AIDS 12(16), 2177–2184 (1998).
   PubMed Web of Science ®Google Scholar
• French N, Gilks CF, Mujugira A, Fasching C, O’Brien J, Janoff EN. Pneumococcal vaccination in HIV-1-infected adults in Uganda: humoral response and two vaccine failures. AIDS 12(13), 1683–1689 (1998).
   PubMed Web of Science ®Google Scholar
• Kroon FP, van Dissel JT, de Jong JC, van Furth R. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS 8(4), 469–476 (1994).
   PubMed Web of Science ®Google Scholar
• Falco V, Jordano Q, Cruz MJ et al. Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: one year follow-up study. Vaccine 24(14), 2567–2574 (2006).
   PubMed Web of Science ®Google Scholar
• Hung C, Chang S, Su C et al. A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy. HIV Med. 11(1), 54–63 (2010).
   PubMed Web of Science ®Google Scholar
• Breiman RF, Keller DW, Phelan MA et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch. Intern. Med. 160(17), 2633–2638 (2000).
   PubMedGoogle Scholar
• French N, Nakiyingi J, Carpenter LM et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 355(9221), 2106–2111 (2000).
   PubMed Web of Science ®Google Scholar
• Watera C, Nakiyingi J, Miiro G et al. 23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort. AIDS 18(8), 1210–1213 (2004).
   PubMed Web of Science ®Google Scholar
• Pedersen R, Lohse N, Østergaard L, Søgaard O. The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review. HIV Med. 12(6), 323–333 (2011).
   PubMed Web of Science ®Google Scholar
• Lesprit P, Pedrono G, Molina JM et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 21(18), 2425–2434 (2007).
   PubMed Web of Science ®Google Scholar
• Penaranda M, Payeras A, Cambra A, Mila J, Riera M. Conjugate and polysaccharide pneumococcal vaccines do not improve initial response of the polysaccharide vaccine in HIV-infected adults. AIDS 24(8), 1226–1228 (2010).
   PubMed Web of Science ®Google Scholar
• Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine 19(7–8), 886–894 (2000).
   PubMed Web of Science ®Google Scholar
• Crum-Cianflone NF, Huppler Hullsiek K, Roediger M et al. A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults. J. Infect. Dis. 202(7), 1114–1125 (2010).
   PubMed Web of Science ®Google Scholar
• Miiro G, Kayhty H, Watera C et al. Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine. J. Infect. Dis. 192(10), 1801–1805 (2005).
   PubMed Web of Science ®Google Scholar
• Ahmed F, Steinhoff MC, Rodriguez-Barradas MC, Hamilton RG, Musher DM, Nelson KE. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial. J. Infect. Dis. 173(1), 83–90 (1996).
   PubMed Web of Science ®Google Scholar
• Pickering LK. Report of the Committee on Infectious Diseases. American Academy of Pediatrics, Elk Grove, IL, USA (2012).
   Google Scholar